EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The bisbenzimide compound ridinilazole has antiviral activity against vaccinia and mpox viruses

Misbah El-Jesr, Lucy Eke, Blair L Strang, Carlos Maluquer de Motes, Rebecca P Sumner

Journal of General Virology · 02.11.2026 · 107 (11)

DOI: 10.1099/jgv.0.002363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of General Virology, erschienen am 02.11.2026. Verfasst von Misbah El-Jesr und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbial Sciences, University of Surrey, Guildford GU2 7XH, UK. Hauptthemen laut MEDLINE: Antiviral Agents, Vaccinia virus, Monkeypox virus. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, Royal Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mpox remains a significant global public health threat, highlighting the need for new antiviral therapies. Ridinilazole is a symmetric bisbenzimide developed for the treatment of Clostridium difficile infection that has recently been shown to inhibit human cytomegalovirus. Here, we investigated its antiviral activity against orthopoxviruses (OPXV). Ridinilazole potently inhibited vaccinia virus replication in primary human foreskin fibroblasts, with an IC 50 of 21 nM and minimal cytotoxicity. Importantly, ridinilazole also reduced infectious monkeypox virus (the causative agent of mpox) yields in primary fibroblasts by more than 150-fold. Mechanistic studies demonstrated that ridinilazole did not affect early viral gene expression or viral DNA replication, but significantly reduced the expression of late viral genes at both transcript and protein levels. These findings identify ridinilazole as an effective inhibitor of OPXV replication and support its potential repurposing as a novel therapeutic for mpox.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsVaccinia virusMonkeypox virusHumansVirus ReplicationFibroblastsAnimalsCells, Cultured

Stichwörter der Autor:innen

antiviralbisbenzimidempoxorthopoxvirusridinilazolevaccinia virus

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Microbial Sciences, University of Surrey, Guildford GU2 7XH, UK.
  • Institute of Infection & Immunity, St George's School of Health and Medical Sciences, City St George's, University of London, London, SW19 0RE, UK.
  • Department of Infectious Diseases, King's College London, London SE1 9RT, UK.

Förderung

  • Biotechnology and Biological Sciences Research Council
  • Royal Society

Zitieren

APA

El-Jesr, M., Eke, L., Strang, B. L., Maluquer de Motes, C., & Sumner, R. P. (2026). The bisbenzimide compound ridinilazole has antiviral activity against vaccinia and mpox viruses. Journal of General Virology, 107(11). https://doi.org/10.1099/jgv.0.002363

Vancouver

El-Jesr M, Eke L, Strang BL, Maluquer de Motes C, Sumner RP. The bisbenzimide compound ridinilazole has antiviral activity against vaccinia and mpox viruses. Journal of General Virology. 2026;107(11). doi:10.1099/jgv.0.002363

BibTeX
@article{ElJesr2026,
  author = {El-Jesr, Misbah and Eke, Lucy and Strang, Blair L and Maluquer de Motes, Carlos and Sumner, Rebecca P},
  title = {The bisbenzimide compound ridinilazole has antiviral activity against vaccinia and mpox viruses},
  journal = {Journal of General Virology},
  year = {2026},
  volume = {107},
  number = {11},
  doi = {10.1099/jgv.0.002363}
}
Kostenlos starten →